相关实验视频
Updated: Jan 13, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
901
胰岛素治疗和肥胖:当前和未来的药理学可能性
Emory Moss1, Kennedy Hawk2, Kathrine Lollis3
1University of South Carolina College of Pharmacy, Columbia, United States; MOSSEA@email.sc.edu.
Canadian journal of physiology and pharmacology
|January 7, 2026
概括
基于因克雷的疗法,包括双重和三重受体激动剂,在控制肥胖方面表现有前途. 这些治疗针对关键激素来调节食欲和能量平衡,提供个性化的未来选择.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖是一个全球性流行病,具有复杂的促成因素.
- 它给个人健康和医疗保健系统带来了重大挑战.
- 了解能量平衡的荷尔蒙调节至关重要.
研究的目的:
- 探索用于肥胖管理的基于英克雷丁的疗法.
- 专注于超越单个受体激动剂的新型药物.
- 讨论个性化cretin向治疗的未来方向.
主要方法:
- 关键代谢激素 (GLP-1,GIP,氨酸,葡萄糖) 的生理功能审查.
- 探索双重和三重受体激动剂药理学.
- 讨论创新的药物输送系统和潜在的目标.
主要成果:
- 基于因克雷丁的疗法在肥胖管理方面显示出潜力.
- 双重和三重受体激动剂代表了新的治疗方法.
- 个性化医疗提供了量身定制的治疗策略.
结论:
- 针对因克雷的向疗法正在成为下一代肥胖治疗方法.
- 这些疗法可以达到显著的结果,根据个体需求量身定制.
- 对新的目标和交付系统进行进一步的研究是有必要的.
相关概念视频
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
Drug Dosing: Obese Patients
217
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
217
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581

